interest. Readers are encouraged to conduct their own independent research and consult qualified financial, legal, medical, or other professional advisers before making any investment or health-related decisions.Forward-looking statements referenced in this article are subject to risks and uncertainties, and actual results may differ materially. Past performance is not indicative of future results.For full disclosures, risk factors, and forward-looking statements, please visit: [https://moonage.media/discla ...

Core Insights - Polyrizon Ltd. has initiated a key usability study for its lead product candidate, NASARIX™, aimed at confirming alignment with FDA requirements and supporting clinical development [1][2] Group 1: Product Development - NASARIX™ is an innovative intranasal allergy blocker designed for broad consumer use, representing a significant advancement in Polyrizon's development roadmap [1][2] - The usability study is intended to de-risk downstream regulatory review and facilitate a streamlined path toward clinical trials [2][3] Group 2: Regulatory Milestones - Successful completion of the usability program will provide essential regulatory evidence for NASARIX™'s readiness for clinical evaluation, with trials expected to commence in Q3 2026 [3][4] - The study underscores the company's commitment to FDA-aligned development, patient safety, and user-centered solutions [4] Group 3: Company Overview - Polyrizon specializes in developing innovative medical device hydrogels delivered as nasal sprays, which create a barrier against viruses and allergens [4] - The proprietary Capture and Contain™ hydrogel technology aims to function as a "biological mask" in the nasal cavity, with ongoing development focused on enhancing bioadhesion and retention [4]

Core Insights - Polyrizon Ltd. has completed the branding process for its PL-14 allergy blocker, which will be marketed as NASARIX™ [1][4] - NASARIX™ utilizes Polyrizon's proprietary Capture and Contain™ hydrogel technology, designed to create a protective barrier against allergens and viruses [2][5] - The establishment of the NASARIX™ brand is a significant milestone for Polyrizon, aiding in future commercialization and effective communication of the product's benefits [2][4] Company Overview - Polyrizon is a pre-clinical-stage biotechnology company focused on developing innovative medical device hydrogels delivered as nasal sprays [5] - The company's C&C hydrogel technology aims to provide a barrier against viruses and allergens, functioning as a "biological mask" in the nasal cavity [5] - Polyrizon is also developing additional technology for nasal delivery of active pharmaceutical ingredients, referred to as Trap and Target™ [5]